Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 626 to 650 of 1141 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
516 increased binding (GO:0005488) FKBP12 (Arabidopsis thaliana) (TAIR:AT5G64350) 980: Inhibition, Calcineurin Activity
515 increased binding (GO:0005488) FK506-binding protein 15 (PR:000007535) 980: Inhibition, Calcineurin Activity
514 increased Immunosuppression (MESH:D007165) None
513 decreased cytokine production involved in inflammatory response (GO:0002534) NFAT activation molecule 1 (PR:000011161) 981: Reduction, NFAT/AP-1 complex formation
512 increased genetic interference (MI:0254) NFAT protein (PR:000003112) 979: Interference, nuclear localization of NFAT
511 abnormal ovulation cycle (GO:0042698) 971: Ovulation of oocytes Reduced, Delayed, or Blocked, Decrease or delay in LH surge required for ovulation
510 decreased luteinizing hormone secretion (GO:0032275) Luteinizing hormone (CHEBI:81568)
509 decreased neurotransmitter secretion (GO:0007269) metastasis-suppressor KiSS-1 (rat) (PR:Q7TSB7) None
508 decreased estrogen (CHEBI:50114) None
507 decreased signaling (GO:0023052) aromatase (PR:000006100) 964: Inhibition of Aromatase Enzyme, Chemical exposure during critical window of estrous cycle between diestrus 2 and proestrus inhibits aromatase conversion of testosterone to estradiol
506 increased metabolic process (GO:0008152) thyroxine (CHEBI:30660) 961: Increased, Clearance of thyroxine from serum
505 increased transport (GO:0006810) thyroxine (CHEBI:30660) 960: Increased, Uptake of thyroxine into tissue
504 increased thyroxine (CHEBI:30660)
503 increased binding (GO:0005488) transthyretin (PR:000016801) 957: Binding, Transthyretin in serum
502 decreased protein dimerization activity (GO:0046983) aryl hydrocarbon receptor nuclear translocator (PR:000004303) 945: reduced dimerization, ARNT/HIF1-alpha
501 decreased protein dimerization activity (GO:0046983) hypoxia-inducible factor 1-alpha (PR:000008555) 945: reduced dimerization, ARNT/HIF1-alpha
500 increased protein dimerization activity (GO:0046983) aryl hydrocarbon receptor nuclear translocator (PR:000004303) 944: dimerization, AHR/ARNT
499 increased protein dimerization activity (GO:0046983) aryl hydrocarbon receptor (PR:000003858) 944: dimerization, AHR/ARNT
498 decreased gene expression (GO:0010467) vascular endothelial growth factor A (PR:000017284) 948: reduced production, VEGF
497 increased embryonic lethality (MP:0008762) 947: Increase, Early Life Stage Mortality
496 increased pericardial edema (MP:0001787) 358: Increase, Pericardial edema
495 abnormal cardiovascular system development (GO:0072358) cardiovascular system (UBERON:0004535) 317: Altered, Cardiovascular development/function
494 functional change nitric oxide synthase, endothelial (PR:000011328) 932: KE4 : Uncoupling, eNOS
493 increased protein glutathionylation (GO:0010731) cysteine residue (CHEBI:32460) 927: KE1 : S-Glutathionylation, eNOS
492 increased protein glutathionylation (GO:0010731) nitric oxide synthase, endothelial (PR:000011328) 927: KE1 : S-Glutathionylation, eNOS